The abstract is read at the publisher; the summary is JClub's.
DHHC7 (ZDHHC7) palmitoylates KRAS4A on Cys180, promoting plasma membrane localization and nanoclustering that activates ARAF and RAF1 in pancreatic cancer models.
- Why it matters: KRAS-mutant cancers often need additional strategies beyond KRAS inhibitors, especially where resistance limits durable responses.
- What they did: The study mapped KRAS4A palmitoylation to Cys180 and tested how DHHC7 and Cys180 palmitoylation affect membrane localization, nanoclustering, RAF signaling, and growth in pancreatic cancer cell lines and mouse xenografts.
- The result: DHHC7 and KRAS4A Cys180 palmitoylation support normal and anchorage-independent growth, and ZDHHC7 depletion dramatically inhibits pancreatic tumor growth in mouse xenograft models, suggesting DHHC7 as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.